Bradley Zerler

Vice President at

P.O. Box 7142, Bellevue, Washington, United States

General Information

Employment History

Vice President, Research  - CollaGenex Pharmaceuticals , Inc.

Director of Biology  - Locus Pharmaceuticals Inc


PhD  - 

Web References  

CollaGenex Pharmaceuticals, Inc. Investor Relations

and Strategic Planning, and Brad Zerler, the Company's Vice President of Research.These options were granted without stockholder approval pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) under the 40,000, non-qualified stock options to Mr. Zerler, each with exercise

Read More
CollaGenex Pharmaceuticals, Inc. Investor Relations

CollaGenex Pharmaceuticals Appoints J. Gregory Ford as VP, Business Development, and Bradley Zerler, PhD, as VP, ResearchCollaGenex Pharmaceuticals, Inc.CollaGenex Pharmaceuticals Appoints J. Gregory Ford as VP, Business Development, and Bradley Zerler, PhD, as VP, Research Strategic Planning, and Bradley Zerler, PhD, as Vice President, Research. "The addition of Greg Ford and Brad Zerler will further strengthen Brad will oversee our Bradley Zerler, PhD, as Vice President, Research Dr. Zerler brings more than 15 years of research and development experience at domestic and international life sciences companies.He Prior to re-joining CollaGenex, Dr. Zerler was Director of Biology for Locus Pharmaceuticals, Inc., a privately held pharmaceutical company focused on developing novel, small molecule therapeutic drugs. Dr. Zerler worked for CollaGenex from 1997 through 2001 as Director of Research, when the Company launched its flagship product, Periostat(R), the first and only systemic treatment for adult periodontitis.Dr. Zerler initially joined CollaGenex from Bayer where he spent more than 10 years in its Biotechnology and Research divisions.

Read More
InterWest Partners - Investing in Information Technology & Life Sciences

Brad Zerler, VP of research at CollaGenex, agreed that care should be taken when directly targeting MMPs.
"MMPs play an important temporal role in wound healing and tissue remodeling," he said. "Consequently, there are times when inhibition may be appropriate; but there are times when the enzymes are required and, for those reasons, inhibition would be inappropriate. Therefore, inhibition of MMPs post-trauma may be quite tricky in regard to timing and needed tissue repair and remodeling." Zerler said doxycycline is less potent than other MMPIs, which he said could account for the lower incidence of side effects. "Most in the field think of MMP inhibition in terms of treating chronic conditions, and perhaps that is why their development has been somewhat disappointing," he said. He proposed that treatment of acute, rather than chronic, pain "may just be the niche for this class of compounds." But, Zerler added, the Nature Medicine paper "suggests that inhibition of downstream mediators such as IL-1 or perhaps p38 may be more appropriate targets for neuropathic pain."

Read More

Browse ZoomInfo’s Directories